Literature DB >> 17304507

N6-isopentenyladenosine: a potential therapeutic agent for a variety of epithelial cancers.

Monica Spinola1, Francesca Colombo, F Stefania Falvella, Tommaso A Dragani.   

Abstract

Isopentenyladenosine (i(6)A) is a product of isopentenyltransferases and, in mammals, occurs either bound to tRNA or as a free nucleoside. Sporadic reports have suggested an anticancer effect of i(6)A, mostly on leukemia cells. The present analysis of 9 human epithelial cancer cell lines derived from different types of malignant tissue revealed complete suppression of clonogenic activity in 8 of the lines after exposure to i(6)A at a concentration of 10 muM. Mechanistic studies showed that i(6)A tumor suppressor activity is associated with inhibition of cell proliferation, a block in DNA synthesis and morphological changes. These results point to i(6)A and to its possible derivatives as a new potential class of wide-spectrum anticancer agents.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17304507     DOI： 10.1002/ijc.22601

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


  9 in total

Review 1.  Codon-biased translation can be regulated by wobble-base tRNA modification systems during cellular stress responses.

Authors:  Lauren Endres; Peter C Dedon; Thomas J Begley
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

2.  The isoprenoid derivative N6 -benzyladenosine CM223 exerts antitumor effects in glioma patient-derived primary cells through the mevalonate pathway.

Authors:  Elena Ciaglia; Manuela Grimaldi; Mario Abate; Mario Scrima; Manuela Rodriquez; Chiara Laezza; Roberta Ranieri; Simona Pisanti; Pierangela Ciuffreda; Clementina Manera; Patrizia Gazzerro; Anna Maria D'Ursi; Maurizio Bifulco
Journal:  Br J Pharmacol       Date:  2017-06-11       Impact factor: 8.739

3.  Lack of tRNA modification isopentenyl-A37 alters mRNA decoding and causes metabolic deficiencies in fission yeast.

Authors:  Tek N Lamichhane; Nathan H Blewett; Amanda K Crawford; Vera A Cherkasova; James R Iben; Thomas J Begley; Philip J Farabaugh; Richard J Maraia
Journal:  Mol Cell Biol       Date:  2013-05-28       Impact factor: 4.272

4.  N6-isopentenyladenosine dual targeting of AMPK and Rab7 prenylation inhibits melanoma growth through the impairment of autophagic flux.

Authors:  Roberta Ranieri; Elena Ciaglia; Giuseppina Amodio; Paola Picardi; Maria Chiara Proto; Patrizia Gazzerro; Chiara Laezza; Paolo Remondelli; Maurizio Bifulco; Simona Pisanti
Journal:  Cell Death Differ       Date:  2017-10-13       Impact factor: 15.828

5.  Putative role of the adenosine A(3) receptor in the antiproliferative action of N (6)-(2-isopentenyl)adenosine.

Authors:  Clara C Blad; Jacobien K von Frijtag Drabbe Künzel; Henk de Vries; Thea Mulder-Krieger; Sara Bar-Yehuda; Pnina Fishman; Adriaan P Ijzerman
Journal:  Purinergic Signal       Date:  2011-07-01       Impact factor: 3.765

6.  N(6)-isopentenyladenosine and analogs activate the NRF2-mediated antioxidant response.

Authors:  Alice Dassano; Mariateresa Mancuso; Paola Giardullo; Loris De Cecco; Pierangela Ciuffreda; Enzo Santaniello; Anna Saran; Tommaso A Dragani; Francesca Colombo
Journal:  Redox Biol       Date:  2014-03-06       Impact factor: 11.799

7.  Identification of breast cancer candidate genes using gene co-expression and protein-protein interaction information.

Authors:  Zhenyu Yue; Hai-Tao Li; Yabing Yang; Sajid Hussain; Chun-Hou Zheng; Junfeng Xia; Yan Chen
Journal:  Oncotarget       Date:  2016-06-14

8.  N6-Isopentenyladenosine Inhibits Colorectal Cancer and Improves Sensitivity to 5-Fluorouracil-Targeting FBXW7 Tumor Suppressor.

Authors:  Donatella Fiore; Chiara Piscopo; Maria Chiara Proto; Michele Vasaturo; Fabrizio Dal Piaz; Bruno Marcello Fusco; Cristina Pagano; Chiara Laezza; Maurizio Bifulco; Patrizia Gazzerro
Journal:  Cancers (Basel)       Date:  2019-09-28       Impact factor: 6.639

9.  N (6)-substituted AMPs inhibit mammalian deoxynucleotide N-hydrolase DNPH1.

Authors:  Claire Amiable; Sylvie Pochet; André Padilla; Gilles Labesse; Pierre Alexandre Kaminski
Journal:  PLoS One       Date:  2013-11-19       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.